AstraZeneca plc (LON:AZN)’s share price traded up 2.1% on Monday after Jefferies Group raised their price target on the stock from GBX 4,350 to GBX 4,800. Jefferies Group currently has a hold rating on the stock. AstraZeneca plc traded as high as GBX 4,943.50 ($63.84) and last traded at GBX 4,890 ($63.15). 3,825,582 shares traded hands during trading, an increase of 77% from the average session volume of 2,160,170 shares. The stock had previously closed at GBX 4,790 ($61.86).

Several other equities analysts have also weighed in on the stock. Societe Generale restated a “buy” rating on shares of AstraZeneca plc in a research report on Monday. Bryan, Garnier & Co upgraded shares of AstraZeneca plc to a “buy” rating and raised their target price for the stock from GBX 4,700 ($60.70) to GBX 5,380 ($69.48) in a report on Monday. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and issued a GBX 3,800 ($49.08) target price on shares of AstraZeneca plc in a report on Monday. Deutsche Bank AG raised their target price on shares of AstraZeneca plc from GBX 5,300 ($68.45) to GBX 5,600 ($72.32) and gave the stock a “buy” rating in a report on Monday. Finally, HSBC Holdings plc reiterated a “reduce” rating and issued a GBX 4,100 ($52.95) target price on shares of AstraZeneca plc in a report on Monday. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of GBX 4,963.82 ($64.11).

In other news, insider Nazneen Rahman purchased 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

The company’s 50-day moving average price is GBX 4,571.40 and its 200-day moving average price is GBX 4,878.32. The stock’s market cap is GBX 61.91 billion.

AstraZeneca plc (LON:AZN) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. On average, equities research analysts forecast that AstraZeneca plc will post $3.75 EPS for the current year.

The business also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a GBX 68.90 ($0.89) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Trading 2.1% Higher on Analyst Upgrade” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/12/astrazeneca-plc-azn-trading-2-1-higher-on-analyst-upgrade.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.